RedHill Biopharma Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price; Faces 180-Day Compliance Period
RDHL is trading near its 52-week low of $0.71 (14% above the low).
Summary
RedHill Biopharma received a Nasdaq delisting notice due to its stock trading below the $1.00 minimum bid price, initiating a 180-day period to regain compliance.
Key Events · Legal and Risk Events · RDHL
-
Nasdaq Delisting Notice Received
On April 8, 2026, RedHill Biopharma Ltd. received a letter from Nasdaq's Listings Qualifications Department.
-
Non-Compliance with Minimum Bid Price
The notice indicates the company's American Depositary Shares (ADSs) closed below the minimum $1.00 per share requirement for 30 consecutive business days (February 20, 2026, to April 2, 2026).
-
180-Day Compliance Period
RedHill has an initial period of 180 calendar days, until October 5, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2).
-
Regaining Compliance
Compliance can be achieved if the ADSs close at $1.00 or more for a minimum of ten consecutive business days before the deadline.
Analysis · RDHL · Life Sciences
RedHill Biopharma has received a formal notice from Nasdaq regarding its failure to maintain the minimum $1.00 bid price requirement. This is a critical event as continued non-compliance could lead to delisting, severely impacting the company's liquidity and access to capital markets. While the company has 180 days to regain compliance, the notice itself signals significant operational and financial challenges, especially for a company with a small market capitalization. Investors should monitor the stock price performance closely and any strategic actions the company may take to address this deficiency, such as a reverse stock split.
At the time of this filing, RDHL was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $0.71 to $3.31. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.